Skip to main content
Clinical Trials/ACTRN12609000270213
ACTRN12609000270213
Not Yet Recruiting
Phase 4

An open trial of a Cognitive Behavioural Therapy (CBT)-based smoking cessation plus Varenicline intervention in people with a psychotic disorder

Pfizer Australia (Investigator Initiated Grant)0 sites15 target enrollmentMay 15, 2009

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Smoking cessation in people with a psychotic illness.
Sponsor
Pfizer Australia (Investigator Initiated Grant)
Enrollment
15
Status
Not Yet Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Pfizer Australia (Investigator Initiated Grant)

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years and over; Diagnosis of a psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, etc.) and on stable psychiatric medication for at least three months; Current heavy smoker (at least 15 cigarettes per day).

Exclusion Criteria

  • (1\) Non\-psychotic illness; (2\) People who are smoking fewer than 15 cigarettes per day; (3\) Non\-English speakers; (4\) People with organic brain diseases; (4\) An unstable psychiatric (eg., actively suicidal) or medical condition (eg., uncontrolled diabetes); (5\) People with any specific contraindication to the use of varenicline; (6\) Pregnant women.

Outcomes

Primary Outcomes

Not specified

Similar Trials